Compare Sana Biotechnology Inc (SANA) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Tempus AI — how do they compare? Sana Biotechnology Inc trades at $3.78 (market cap $1.01B), while Tempus AI trades at $55.76 (market cap $9.93B). The key difference: Tempus AI is far larger — about 9.8× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| SANA | TEM | |
|---|---|---|
Market Cap | $1.01B | $9.93B |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $103.25 |
52-Week Low | $2.68 | $41.55 |
Enterprise Value | $980.22M | $10.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.52, up 3.23% with a bullish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn improved in 2026. Recent positive developments include clinical data presentations and a $69M stock offering. Analyst consensus remains strong with 82% buy ratings and a $9.50 price target.
While SANA shows promising clinical progress and strong analyst support, significant financial losses and cash burn present substantial risks. The stock's upside potential depends on successful clinical trial outcomes and path to profitability, making it suitable for risk-tolerant investors seeking biotech exposure.
Tempus AI (TEM) trades at $52.05, up 12.86% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat revenue estimates and raised 2026 sales guidance. The stock is technically bullish with moving averages supporting upside, while fundamentals show revenue growth to $1.4 billion in 2026 but persistent net losses. Recent news highlights expansion through the Personalis acquisition and AI-driven precision medicine advancements.
Outlook: Growth prospects are robust with AI adoption in healthcare and strategic deals, but high valuation ratios and negative profitability pose risks. Analysts are bullish with a $61.57 consensus target, though cash burn and competitive pressures require monitoring for sustained investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
